MedTech logo

t: 0161 820 8440



Phagenesis gains CE mark for dysphagia treatment.


Phagenesis  Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) have been awarded a CE Mark for their Phagenyx™ treatment system.


Dysphagia, the inability to swallow safely, is a debilitating condition that affects about half of all stroke patients . Dysphagia frequently leads to potentially life-threatening pneumonia and the surgical implantation of a PEG tube to allow a patient to be fed through the abdomen wall indefinitely.


The Phagenyx™ treatment system delivers a calibrated electrical signal to the back of the throat (oropharynx) for 10 minutes a day for three consecutive days. This protocol has shown to lead to a clinically and statistically significant improvement inswallowing function in a majority of dysphagia patients.

The CE Mark paves the way for Phagenyx to be launched in the European Union, where there are more than 1 million strokes per year.


Phagenesis was the first MedTECH Centre company and Phagenyx is the result of research and development, led by Professor Shaheen of the Salford Royal Hospital and the University of Manchester.


Having started with two employees in the MedTECH Centre in 2010, the company has grown to nine staff and this latest achievement puts them well on course to enter the market in 2013.

back to news listing

Supported by:

Central Manchester University Hospitals logoManchester Science Parks logoTrusTECH logo